Dube Eric M 4

What Happened
Eric M. Dube, CEO of Travere Therapeutics (TVTX), exercised 60,000 stock options at $15.46 per share (cost $927,600) on Feb 20, 2026, and sold 60,000 shares in the open market that same day for $30.10 per share (proceeds $1,805,766). The Form 4 also reports a 60,000-share derivative disposition at $0; the filing does not provide further detail on that line.

Key Details

• Transaction date: February 20, 2026; Form 4 filed February 24, 2026 (filing within the usual two-business-day window).
• Exercise: 60,000 options (code M) at $15.46 each — total cash paid $927,600. Option is fully vested/​exercisable (Footnote F3).
• Sale: 60,000 shares (code S) in an open market sale at a weighted average of $30.0961; reported proceeds $1,805,766. Sale made under a written 10b5-1 plan adopted June 16, 2025 (Footnote F1). Range of sale prices: $30.00–$30.325 (Footnote F2).
• Additional line: 60,000-share derivative conversion/disposition listed at $0 (code M) — filing provides no explanation for this entry.
• Shares owned after the transactions: not specified in the provided filing.

Context
This sequence (exercise of options followed by an immediate sale of the same shares) is common when executives exercise vested options and sell shares to cover costs or diversify; here the sale was executed under a pre-established 10b5-1 plan. The filing is factual and does not state motivation.